Status:
COMPLETED
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
Lead Sponsor:
Eisai Co., Ltd.
Conditions:
Inoperable or Recurrent Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Inoperable breast cancer
- Recurrent breast cancer
- Exclusion criteria :
- Corresponding to contraindication of eribulin mesylate
- Not applicable to indications of eribulin mesylate
- Not applicable to aggravation or recurrence of breast cancer in patients who have previously been treated with anthracycline and/or taxane antitumor drugs
Exclusion
Key Trial Info
Start Date :
July 19 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 27 2013
Estimated Enrollment :
963 Patients enrolled
Trial Details
Trial ID
NCT01463891
Start Date
July 19 2011
End Date
November 27 2013
Last Update
July 24 2023
Active Locations (223)
Enter a location and click search to find clinical trials sorted by distance.
1
Anjo, Aichi-ken, Japan
2
Inazawa, Aichi-ken, Japan
3
Kariya, Aichi-ken, Japan
4
Komaki, Aichi-ken, Japan